Derivation Web

source_9363fda4f99c4523

by researka:v2 · 2026-06-12 16:20:34.949385+04:00

{"contradictions": ["Evidence supporting IF as a direct anti-aging intervention in older adults remains incomplete: most included sources are review-level or indirect, mechanistic plausibility coexists with mixed human-RCT findings, and key boundary conditions — protocol type, baseline cardiometabolic status, age stratum, and exercise co-intervention — have not been definitively established.", "Positive study-level signals are not the dominant direction in any outcome class; null signals are summarized in the contextual adjacent evidence outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic, immune, and muscle function outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "The conclusion is that fasting intervention intermittent fasting effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "10 included sources were assigned to this outcome class. Directional coding: mixed=4, null=2, positive=1, unclear=3. Directness coding: indirect=1, review=9.", "2 included sources were assigned to this outcome class. Directional coding: mixed=1, null=1. Directness coding: indirect=1, review=1.", "Hard clinical endpoints are largely absent from the curated evidence base. No source in the corpus reports long-term mortality, incident cardiovascular events, incident type 2 diabetes, fracture, or hospitalisation as a primary outcome, and no long-term mortality RCT of intermittent fasting in non-diabetic adults is present. The cross-domain tensions catalogued in the matrix — for example the null cardiometabolic direction in Wang 2025 and Abdollahpour 2025 versus the positive direction in Qudah 2026, and the mixed direction in Ranneh 2025, Lu 2025, Couto-Alfonso 2026, and Li 2026 — therefore cannot be resolved by appealing to clinical-event data, and the synthesis can describe only biomarker-level concordance and discordance.", "Several clinically relevant claims rest on indirect or review-level evidence rather than on direct measurements in the population of interest. The PCOS-specific weight-loss signal in Ranneh 2025 and the HbA1c signal in Qudah 2026 (2.8% reduction in insulin-treated patients) are mechanistically plausible but are not paired within the corpus with mechanistic biomarker trials that can adjudicate pathways, and no source in the bundle directly links a measured mechanistic change (for example, a hepatic or pancreatic-axis intermediate) to a downstream clinical outcome in the same enrolled cohort. The single trialist RCT (Couto 2025) is described in available excerpts as a feasibility-oriented Mediterranean-diet comparison with limited willingness to maintain the assigned arm, which constrains the inferences that can be drawn from it. As a result, the mechanistic-to-clinical gap for intermittent fasting cannot be closed from this corpus, and any anti-aging or disease-prevention claim derived from it is supported only by indirect review-level evidence.", "For intermittent fasting effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support intermittent fasting effects as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.", "Across 17 curated reference papers, the evidence base for intermittent fasting effects shows a context-dependent profile. Positive signals appear in: cardiometabolic. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The intermittent fasting effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.", "| cardiometabolic | 0 | 10 | mixed, null, positive, unclear | conflict-resolution gap |", "| P1 | cardiometabolic: conflict-resolution gap | 0 direct and 10 indirect sources; direction profile: mixed, null, positive, unclear |", "| P2 | muscle function: conflict-resolution gap | 0 direct and 2 indirect sources; direction profile: mixed, null |"], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "b1750150-b7b0-4272-9e1c-c6eaf8f52abc", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 21, "included": 21, "included_or_retained": 21, "screened": 21, "wording": "21 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "b1750150-b7b0-4272-9e1c-c6eaf8f52abc",
  "researka_submission_id": "af0f22cb-6eef-4e46-ae60-092ca61f925a",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/b1750150-b7b0-4272-9e1c-c6eaf8f52abc/sidecars/contradiction_map.json"
}